- Home
- AMIX vs ACON Comparison
AMIX vs ACON Comparison
Compare AMIX & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMIX
- ACON
- Stock Information
- Founded
- AMIX 2014
- ACON 2008
- Country
- AMIX United States
- ACON United States
- Employees
- AMIX N/A
- ACON N/A
- Industry
- AMIX
- ACON Retail: Computer Software & Peripheral Equipment
- Sector
- AMIX
- ACON Technology
- Exchange
- AMIX NYSE
- ACON Nasdaq
- Market Cap
- AMIX 4.9M
- ACON 4.8M
- IPO Year
- AMIX N/A
- ACON 2022
- Fundamental
- Price
- AMIX $1.48
- ACON $6.87
- Analyst Decision
- AMIX Strong Buy
- ACON Buy
- Analyst Count
- AMIX 1
- ACON 2
- Target Price
- AMIX $5.00
- ACON $481.00
- AVG Volume (30 Days)
- AMIX 441.4K
- ACON 17.8K
- Earning Date
- AMIX 05-29-2025
- ACON 05-15-2025
- Dividend Yield
- AMIX N/A
- ACON N/A
- EPS Growth
- AMIX N/A
- ACON N/A
- EPS
- AMIX N/A
- ACON N/A
- Revenue
- AMIX N/A
- ACON $54,601.00
- Revenue This Year
- AMIX N/A
- ACON $212.31
- Revenue Next Year
- AMIX N/A
- ACON $92.86
- P/E Ratio
- AMIX N/A
- ACON N/A
- Revenue Growth
- AMIX N/A
- ACON N/A
- 52 Week Low
- AMIX $1.30
- ACON $6.20
- 52 Week High
- AMIX $42.40
- ACON $3,499.51
- Technical
- Relative Strength Index (RSI)
- AMIX 32.78
- ACON 36.90
- Support Level
- AMIX $1.30
- ACON $6.29
- Resistance Level
- AMIX $1.84
- ACON $6.80
- Average True Range (ATR)
- AMIX 0.09
- ACON 0.34
- MACD
- AMIX -0.03
- ACON 0.88
- Stochastic Oscillator
- AMIX 15.64
- ACON 65.17
About AMIX AUTONOMIX MEDICAL INC
Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.